Influence of nuclides and chelators on imaging using affibody molecules: Comparative evaluation of recombinant affibody molecules site-specifically labeled with 68Ga and 111In via maleimido derivatives of DOTA and NODAGA

Bioconjugate Chemistry

Volumn 24, Issue 6, 2013, Pages 1102-1109

  Altai, Mohamed ^a   Strand, Joanna ^a   Rosik, Daniel ^a   Selvaraju, Ram Kumar ^b   Eriksson Karlström, Amelie ^a   Orlova, Anna ^b   Tolmachev, Vladimir ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; CHELATION; DISEASES; GALLIUM COMPOUNDS; IMAGE PROCESSING; MOLECULES; TUMORS;

AFFIBODY MOLECULES; BIODISTRIBUTIONS; CHEMICAL NATURE; COMPARATIVE EVALUATIONS; HIGH CONTRAST IMAGING; IMAGING CONTRAST; LABELINGS; PROTEIN EXPRESSIONS; TUMOR UPTAKE; TUMOR-ASSOCIATED PROTEINS;

RADIOISOTOPES;

AFFIBODY MOLECULE; CHELATING AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GALLIUM 68; INDIUM 111; MALEIMIDO DERIVATIVE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVITY; COMPARATIVE STUDY; CONJUGATION; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG UPTAKE; FEMALE; INTERNALIZATION; LIVER METASTASIS; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN BINDING; RADIOACTIVITY; TUMOR XENOGRAFT;

EID: 84879389584     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc300678y     Document Type: Article

References (43)

1. Löfblom, J., Feldwisch, J., Tolmachev, V., Carlsson, J., StaÌŠhl, S., and Frejd, F. Y. (2010) Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications FEBS Lett. 584, 2670-80
2. Ahlgren, S. and Tolmachev, V. (2010) Radionuclide molecular imaging using Affibody molecules Curr. Pharm. Biotechnol. 11, 581-9
3. Orlova, A., Magnusson, M., Eriksson, T. L., Nilsson, M., Larsson, B., Höidén-Guthenberg, I., Widström, C., Carlsson, J., Tolmachev, V., StaÌŠhl, S., and Nilsson, F. Y. (2006) Tumor imaging using a picomolar affinity HER2 binding affibody molecule Cancer Res. 66, 4339-48
4. Yarden, Y. (2001) Biology of HER2 and its importance in breast cancer Oncology 61 (Suppl 2) 1-13
5. Arteaga, C. L., Sliwkowski, M. X., Osborne, C. K., Perez, E. A., Puglisi, F., and Gianni, L. (2012) Treatment of HER2-positive breast cancer: current status and future perspectives Nat. Rev. Clin. Oncol. 9, 16-32
6. Eigenbrot, C., Ultsch, M., Dubnovitsky, A., Abrahmsén, L., and Härd, T. (2010) Structural basis for high-affinity HER2 receptor binding by an engineered protein Proc. Natl. Acad. Sci. U. S. A. 107, 15039-44
7. Kramer-Marek, G., Gijsen, M., Kiesewetter, D. O., Bennett, R., Roxanis, I., Zielinski, R., Kong, A., and Capalam, J. (2012) Potential of PET to predict the response to trastuzumab treatment in an ErbB2-positive human xenograft tumor model J. Nucl. Med. 53, 629-37
8. 68Ga-labeled affibody molecules J. Nucl. Med. 51, 892-7
9. 111In]ABY-025 metastatic detection capability in females with metastatic breast cancer J. Nucl. Med. 53 (Supplement 1) 220
10. EGFR:2377 Affibody molecule: aspect of the injected tracer amount Eur. J. Nucl. Med. Mol. Imaging 37, 613-22
11. IGF1R:4551 J. Nucl. Med. 53, 90-7
12. Kronqvist, N., Malm, M., Gostring, L., Gunneriusson, E., Nilsson, M., Hoiden Guthenberg, I., Gedda, L., Frejd, F. Y., StaÌŠhl, S., and Löfblom, J. (2011) Combining phage and staphylococcal surface display for generation of ErbB3-specific Affibody molecules Protein Eng., Des. Sel. 24, 385-96
13. Lindborg, M., Cortez, E., Hoiden-Guthenberg, I., Gunneriusson, E., von Hage, E., Syud, F., Morrison, M., Abrahmsén, L., Herne, N., Pietras, K., and Frejd, F. Y. (2011) Engineered high-affinity affibody molecules targeting platelet-derived growth factor receptor beta in vivo J. Mol. Biol. 407, 298-315
14. Mume, E., Orlova, A., Larsson, B., Nilsson, A. S., Nilsson, F. Y., Sjöberg, S., and Tolmachev, V. (2005) Evaluation of ((4-hydroxyphenyl) ethyl)maleimide for site-specific radiobromination of anti-HER2 affibody Bioconjugate Chem. 16, 1547-55
15. 124I-labeled affibody molecule and trastuzumab in a murine xenograft model J. Nucl. Med. 50, 417-25
16. 64Cu labeled affibody protein Bioconjugate Chem. 21, 947-54
17. 111In-labelled analogue Eur. J. Nucl. Med. Mol. Imaging 37, 1356-67
18. 68Ga-DOTA-affibody molecule for in vivo assessment of HER2/neu expression with PET Eur. J. Nucl. Med. Mol. Imaging 38, 1967-76
19. HER2:2395 in a mouse model for ovarian cancer J. Nucl. Med. 53, 146-53
20. 18F-labeled protein scaffold molecules J. Nucl. Med. 49, 804-13
21. Tolmachev, V., Altai, M., Sandström, M., Perols, A., Karlström, A. E., Boschetti, F., and Orlova, A. (2011) Evaluation of a maleimido derivative of NOTA for site-specific labeling of affibody molecules Bioconjugate Chem. 22, 894-902
22. 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts Eur. J. Nucl. Med. Mol. Imaging 39, 481-92
23. 111In using a maleimido derivative of NODAGA Nucl. Med. Biol. 39, 518-29
24. 111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors Bioconjugate Chem. 13, 530-41
25. 68Ga-somatostatin antagonists: the chelate makes the difference J. Nucl. Med. 52, 1110-8
26. 68Ga-labeled RGD conjugates show improved PET imaging of α(ν)β(3) integrin expression and facile radiosynthesis J. Nucl. Med. 52, 1276-84
27. 68Ga]NODAGA-RGD for imaging αvβ3 integrin expression Eur. J. Nucl. Med. Mol. Imaging 38, 1303-12
28. Ahlgren, S., Orlova, A., Rosik, D., Sandström, M., Sjöberg, A., Baastrup, B., Widmark, O., Fant, G., Feldwisch, J., and Tolmachev, V. (2008) Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules Bioconjugate Chem. 19, 235-43
29. Tolmachev, V., Tran, T. A., Rosik, D., Sjöberg, A., Abrahmsén, L., and Orlova, A. (2012) Tumor targeting using affibody molecules: interplay of affinity, target expression level, and binding site composition J. Nucl. Med. 53, 953-60
30. 111In-labeled CHX-A′-DTPA-trastuzumab and anti-HER2 ABY-025 Affibody molecule by prostate cancer cell lines Exp. Ther. Med. 2, 523-528
31. HER2:342-pep2: implications for development of labeled tracers Cancer Biother. Radiopharm. 23, 435-42
32. 111In-labeled synthetic anti-HER2 affibody molecules Bioconjugate Chem. 23, 1661-70
33. Heppeler, A., Froidevaux, S., Mäcke, H. R., Jermann, E., Béhé, M., Powell, P., and Hennig, M. (1999) Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor rmediated internal radiotherapy Chem.-Eur. J. 5, 1974-81
34. Broan, C. J., Cox, J. P. L., Craig, A. S., Kataky, R., Parker, D., Harrison, A., Randall, A., and Ferguson, G. J. (1991) Structure and solution stability of indium and gallium complexes of 1,4,7-triazacyclononanetriacetate and of yttrium complexes of 1,4,7,10-tetraazacyclododecanetetraacetate and related ligands: kinetically stable complexes for use in imaging and radioimmunotherapy. X-Ray molecular structure of the indium and gallium complexes of 1,4,7-triazacyclononane-1,4,7-triacetic acid J. Chem. Soc., Perkin Trans. 2, 87-99
35. André, J. P., Maecke, H. R., Zehnder, M., Macko, L., and Akyel, K. G. (1998) 1,4,7-Triazacyclononane-1-succinic acid-4,7-diacetic acid (NODASA): a new bifunctional chelator for radio gallium-labelling of biomolecules Chem. Commun. 1998, 1301-1302
36. Matthews, R. C., Parker, D., Ferguson, G., Kaitner, B., Harisson, A., and Royle, L. (1991) Synthesis and structure of stable indium and gallium complexes of (R)-1,4,7-tris(2′-methylcarboxymethyl)-triazacyclononane Polyhedron 10, 1951-1953
37. Craig, A. S., Helps, I. M., Parker, D., Adams, H., Bailey, N. A., Williams, M. G., Smith, J. M. A., and Ferguson, G. (1989) Crystal and molecular structure of a seven-coordinate chloroindium(III) complex of 1,4,7-triazacyclononanetriacetic acid Polyhedron 8, 2481-2484
38. Ginj, M., Zhang, H., Eisenwiener, K. P., Wild, D., Schulz, S., Rink, H., Cescato, R., Reubi, J. C., and Maecke, H. R. (2008) New pansomatostatin ligands and their chelated versions: affinity profile, agonist activity, internalization, and tumor targeting Clin. Cancer Res. 14, 2019-27
39. 111In labelled DOTA-RGD peptides for imaging of alphavbeta3 integrin expression Eur. J. Nucl. Med. Mol. Imaging 35, 1507-15
40. Barta, P., Malmberg, J., Melicharova, L., StrandgaÌŠrd, J., Orlova, A., Tolmachev, V., Laznicek, M., and Andersson, K. (2012) Protein interactions with HER-family receptors can have different characteristics depending on the hosting cell line Int. J. Oncol. 40, 1677-82
41. Disibio, G. and French, S. W. (2008) Metastatic patterns of cancers: results from a large autopsy study Arch. Pathol. Lab. Med. 132, 931-9
42. Tolmachev, V., WaÌŠllberg, H., Sandström, M., Hansson, M., Wennborg, A., and Orlova, A. (2011) Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels Eur. J. Nucl. Med. Mol. Imaging 38, 531-9
43. Miao, Z., Levi, J., and Cheng, Z. (2011) Protein scaffold-based molecular probes for cancer molecular imaging Amino Acids 41, 1037-47